Professor | Mansoura University | Egypt
Prof. Dr. Nasser Hamed Mousa is a renowned Egyptian medical scientist and hepatologist, serving at the Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt. With a Scopus record of 1,028 citations, 47 scientific publications, and an h-index of 16, he has made exceptional contributions to the fields of hepatology, gastroenterology, metabolic diseases, and translational medicine. Prof. Mousa earned his M.B.B.Ch., M.Sc., and Ph.D. in Hepatology and Gastroenterology from leading Egyptian medical universities, where he developed a strong foundation in internal medicine and liver pathology. Over the years, he has built an impressive professional career focusing on clinical hepatology, particularly viral hepatitis, liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). His research interests encompass liver disease surveillance, nanomedicine, cancer biology, and metabolic dysfunction-associated steatotic liver disease (MASLD). Notably, his recent studies on individualized HCC risk stratification and gold nanoparticle-mediated cancer therapy have gained international recognition for their innovative clinical and molecular insights. Prof. Mousa’s research skills span molecular diagnostics, clinical trial design, bioinformatics-based network pharmacology, and predictive modeling for liver disease outcomes, reflecting his multidisciplinary expertise. His collaboration with national and international research teams underscores his leadership in evidence-based hepatology. Prof. Mousa has also contributed to advancing precision medicine approaches for patients with chronic liver disease, integrating laboratory science with clinical decision-making. Throughout his career, he has received numerous academic honors and institutional recognitions for his excellence in research, publication impact, and contribution to medical innovation. In conclusion, Prof. Dr. Nasser Hamed Mousa stands as a distinguished figure in liver research, embodying excellence in scientific inquiry, clinical innovation, and academic leadership, while his impactful body of work continues to influence global hepatology and improve patient outcomes in Egypt and worldwide.
Profiles: Scopus | ORCID
Featured Publications
-
Mousa, N., Elbaz, S., Elmetwalli, A., Mansour, M., Abdelsalam, M., Abdelaziz, M., Hashem, M., El-Emam, O., El-wakeel, N., Elgamal, A., et al. (2025). A risk stratification score for predicting first episode of upper gastrointestinal bleeding in patients with cirrhosis. Archives of Medical Research.
-
Mousa, N., Elmetwalli, A., Abdel-Razik, A., Mousa, E., Abdelsalam, M., Elbaz, S., El-wakeel, N., Eldars, W., Gad, E., Arafa, M., et al. (2025, September 15). Periodontitis and metabolic dysfunction-associated steatotic liver disease: Emphasizing the clinical interplay between hepatologists and dentists. Odontology.
-
Mousa, N., Elbaz, S., Elmetwalli, A., Abdelsalam, M., Abdelkader, E., Wahba, M., Abdelaziz, M., El-Emam, O., El-wakeel, N., Shaheen, M., et al. (2025, April 16). Neutrophil percentage-to-albumin ratio as a predictor of acute kidney injury in cirrhotic patients: A novel approach utilizing artificial intelligence. American Journal of Nephrology.
-
Shiha, G., Mousa, N., Soliman, R., Mikhail, N. N. H., Elbasiony, M. A., & Khattab, M. (2020, July). Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study. Journal of Viral Hepatitis.
-
Elbaz, S., Mousa, N., Besheer, T., Sheta, T., Taha, K., Awad, M., Effat, N., Elgamal, A., & Abdel-Razik, A. (2020, April 2). Malondialdehyde and C-reactive protein as prognostic markers of hepatocellular carcinoma. British Journal of Biomedical Science.